EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer

María Rosario Chica-Parrado, Gun Min Kim, Yasuaki Uemoto, Fabiana Napolitano, Chang-Ching Lin, Dan Ye, Emmanuel Bikorimana, Yisheng Fang, Kyung-Min Lee, Saurabh Mendiratta, Ariella B Hanker, Carlos L Arteaga

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von María Rosario Chica-Parrado und 11 weiteren Autor:innen. Beteiligte Einrichtung: UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, 75390, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Piperazines, Cyclin-Dependent Kinase 6, Pyridines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Luminal Androgen Receptor (LAR) triple-negative breast cancers (TNBC) express androgen receptors (AR), exhibit high frequency of PIK3CA mutations and intact RB. Herein, we investigated combined blockade of the CDK4/6 and PI3K signaling with palbociclib, alpelisib, and capivasertib, which inhibit CDK4/6, PI3Kα, and AKT1-3, respectively. The combination of palbociclib/capivasertib, but not palbociclib/alpelisib, synergistically inhibited proliferation of MDA-MB-453 and MFM-223 LAR cells [synergy score 7.34 (p = 5.81x10-11) and 4.78 (p = 0.012), respectively]. The AR antagonist enzalutamide was inactive against MDA-MB-453, MFM-223, and CAL148 cells and did not enhance the efficacy of either combination. Palbociclib/capivasertib inhibited growth of LAR patient-derived xenografts more potently than palbociclib/alpelisib. Treatment of LAR cells with palbociclib suppressed phosphorylated-RB and resulted in adaptive phosphorylation/activation of S473 pAKT and AKT substrates GSK3β, PRAS40, and FoxO3a. Capivasertib blocked palbociclib-induced phosphorylation of AKT substrates more potently than alpelisib. Treatment with PI3Kβ inhibitors did not block phosphorylation of AKT substrates, suggesting that PI3Kβ did not mediate the adaptive response to CDK4/6 inhibition. Phosphokinase arrays of MDA-MB-453 cells treated with palbociclib showed time-dependent upregulation of PDGFRβ, GSK3β, STAT3, and STAT6. RNA silencing of PDGFRβ in palbociclib-treated MDA-MB-453 and MFM-223 cells blocked the upregulation of S473 pAKT, suggesting that the adaptive response to CDK4/6 blockade involves PDGFRβ signaling. Finally, treatment with palbociclib and the PDGFR inhibitor CP637451 arrested growth of MDA-MB-453 and MFM-223 cells to the same degree as palbociclib/capivasertib. These findings support testing the combination of CDK4/6 and AKT inhibitors in patients with LAR TNBC, and further investigation of PDGFR antagonists in this breast cancer subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsPiperazinesCyclin-Dependent Kinase 6PyridinesProto-Oncogene Proteins c-aktCyclin-Dependent Kinase 4Receptors, AndrogenXenograft Model Antitumor AssaysAntineoplastic Combined Chemotherapy ProtocolsCell ProliferationHumansAnimalsFemaleCell Line, TumorMicePyrimidinesDrug SynergismSignal TransductionPhenylthiohydantoinBenzamidesProtein Kinase InhibitorsNitrilesPyrrolesThiazoles

Stichwörter der Autor:innen

CDK4/6 blockadePDGFRβPI3K/AKT inhibitorsTargeted therapyTriple negative breast cancer

Substanzen

PiperazinesCyclin-Dependent Kinase 6palbociclibPyridinesProto-Oncogene Proteins c-aktCyclin-Dependent Kinase 4CDK6 protein, humanReceptors, AndrogenCDK4 protein, humancapivasertib

Autor:innen und Institutionen

  • UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, 75390, USA.
  • UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, 75390, USA; Yonsei University College of Medicine, Seoul, South Korea.
  • UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, 75390, USA; Dept. of Life Science, Hanyang University, Seoul, South Korea.
  • UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, 75390, USA. Electronic address: Ariella.Hanker@UTSouthwestern.edu.
  • UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, 75390, USA. Electronic address: Carlos.Arteaga@UTSouthwestern.edu.

Förderung

  • NCI NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • National Cancer Institute
  • Breast Cancer Research Foundation
  • Susan G. Komen

Zitieren

APA

Chica-Parrado, M. R., Kim, G. M., Uemoto, Y., Napolitano, F., Lin, C. C., Ye, D., Bikorimana, E., Fang, Y., Lee, K. M., Mendiratta, S., Hanker, A. B., & Arteaga, C. L. (2024). Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217219

Vancouver

Chica-Parrado MR, Kim GM, Uemoto Y, Napolitano F, Lin CC, Ye D, et al. Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217219

BibTeX
@article{ChicaParrado2024,
  author = {Chica-Parrado, María Rosario and Kim, Gun Min and Uemoto, Yasuaki and Napolitano, Fabiana and Lin, Chang-Ching and Ye, Dan and Bikorimana, Emmanuel and Fang, Yisheng and Lee, Kyung-Min and Mendiratta, Saurabh and Hanker, Ariella B and Arteaga, Carlos L},
  title = {Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217219}
}
Kostenlos starten →